US FDA staff flag 'serious' safety risks for Intercept's NASH treatment

US FDA staff flag 'serious' safety risks for Intercept's NASH treatment The comments come ahead of the first meeting of the FDA's outside advisers on Friday to discuss Intercept's OCA for NASH, which has no approved therapies. The Food and Drug Administration's reviewers flagged increased risk of diabetes and liver injury from using the oral tablets, called obeticholic acid (OCA), for the treatment of nonalcoholic steatohepatitis. https://ift.tt/lmDZbB7